Kersting, Sabina ;
Dubois, Julie ;
Nasserinejad, Kazem...
HOVON CLL study group , Kersting , S , Dubois , J , Nasserinejad , K , Dobber , J A , Mellink , C , van der Kevie-Kersemaekers , A M F , Evers , L M , de Boer , F , Koene , H R , Schreurs , J , van der Klift , M , Velders , G A , van der Spek , E , van der Straaten , H M , Hoogendoorn , M , van Gelder , M , Posthuma , E F M , Visser , H P J , Houtenbos , I , Idink , C A M , Issa , D E , Dompeling , E C , van Zaanen , H C T , Veelken , H , Levenga , H , Tick , L W , Terpstra , W E , Tonino , S H , Boyer , M , Mobasher , M , Levin , M D & Kater , A P 2022 , ' Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe) : primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial ' , The Lancet Haematology , vol. 9 , no. 3 , pp. e190-e199 . https://doi.org/10.1016/S2352-3026(22)00034-5.
,
2022
